{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(24)"],"submitter":["de Luis Roman D"],"pubmed_abstract":["<b>Background and Aims</b>: The present study was designed to investigate SNP rs17300539 in the <i>ADIPOQ</i> gene and its relationships with obesity, metabolic syndrome (MS), and serum circulating adiponectin. <b>Methods</b>: The present design involved a Caucasian population of 329 subjects with obesity. Anthropometric and adiposity parameters, blood pressure, biochemical parameters, and the percentage of patients with metabolic syndrome were recorded. The <i>ADIPOQ</i> gene variant (rs17300539) genotype was evaluated. <b>Results</b>: The percentage of patients with different genotypes of the rs17300539 polymorphism in this sample was 86.0% (n = 283) (GG), 11.2% (n = 37) (GA), and 2.7% (n = 9) (AA). The allele frequency was G (0.76) and A (0.24). Applying the dominant genetic model (GG vs. GA <i>+</i> AA), we reported differences between genotype GG and genotype GA <i>+</i> AA for serum adiponectin levels (Delta: 7.5 ± 1.4 ng/mL; <i>p</i> = 0.03), triglycerides (Delta: 41.1 ± 3.4 mg/dL; <i>p</i> = 0.01), fastingcirculating insulin (Delta: 4.9 ± 1.1 mUI/L; <i>p</i> = 0.02), and insulin resistance as HOMA-IR (Delta: 1.4 ± 0.1 units; <i>p</i> = 0.02). The remaining biochemical parameters were not related to the genotype of obese patients. The percentages of individuals with MS (OR = 2.07, 95% CI = 1.3-3.88; <i>p</i> = 0.01), hypertriglyceridaemia (OR = 2.66, 95% CI = 1.43-5.01; <i>p</i> = 0.01), and hyperglycaemia (OR = 3.31, 95% CI = 1.26-8.69; <i>p</i> = 0.02) were higher in GG subjects than patients with A allele. Logistic regression analysis reported an important risk of the presence of metabolic syndrome in GG subjects (OR = 1.99, 95% CI = 1.21-4.11; <i>p</i> = 0.02) after adjusting for adiponectin, dietary energy intakes, gender, weight, and age. <b>Conclusions</b>: The GG genotype of rs17300539 is associated with hypertriglyceridaemia, insulin resistance, low adiponectin levels, and a high risk of metabolic syndrome and its components."],"journal":["Nutrients"],"pagination":["5028"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10746109"],"repository":["biostudies-literature"],"pubmed_title":["The Polymorphism rs17300539 in the Adiponectin Promoter Gene Is Related to Metabolic Syndrome, Insulin Resistance, and Adiponectin Levels in Caucasian Patients with Obesity."],"pmcid":["PMC10746109"],"pubmed_authors":["de Luis Roman D","Izaola Jauregui O","Primo Martin D"],"additional_accession":[]},"is_claimable":false,"name":"The Polymorphism rs17300539 in the Adiponectin Promoter Gene Is Related to Metabolic Syndrome, Insulin Resistance, and Adiponectin Levels in Caucasian Patients with Obesity.","description":"<b>Background and Aims</b>: The present study was designed to investigate SNP rs17300539 in the <i>ADIPOQ</i> gene and its relationships with obesity, metabolic syndrome (MS), and serum circulating adiponectin. <b>Methods</b>: The present design involved a Caucasian population of 329 subjects with obesity. Anthropometric and adiposity parameters, blood pressure, biochemical parameters, and the percentage of patients with metabolic syndrome were recorded. The <i>ADIPOQ</i> gene variant (rs17300539) genotype was evaluated. <b>Results</b>: The percentage of patients with different genotypes of the rs17300539 polymorphism in this sample was 86.0% (n = 283) (GG), 11.2% (n = 37) (GA), and 2.7% (n = 9) (AA). The allele frequency was G (0.76) and A (0.24). Applying the dominant genetic model (GG vs. GA <i>+</i> AA), we reported differences between genotype GG and genotype GA <i>+</i> AA for serum adiponectin levels (Delta: 7.5 ± 1.4 ng/mL; <i>p</i> = 0.03), triglycerides (Delta: 41.1 ± 3.4 mg/dL; <i>p</i> = 0.01), fastingcirculating insulin (Delta: 4.9 ± 1.1 mUI/L; <i>p</i> = 0.02), and insulin resistance as HOMA-IR (Delta: 1.4 ± 0.1 units; <i>p</i> = 0.02). The remaining biochemical parameters were not related to the genotype of obese patients. The percentages of individuals with MS (OR = 2.07, 95% CI = 1.3-3.88; <i>p</i> = 0.01), hypertriglyceridaemia (OR = 2.66, 95% CI = 1.43-5.01; <i>p</i> = 0.01), and hyperglycaemia (OR = 3.31, 95% CI = 1.26-8.69; <i>p</i> = 0.02) were higher in GG subjects than patients with A allele. Logistic regression analysis reported an important risk of the presence of metabolic syndrome in GG subjects (OR = 1.99, 95% CI = 1.21-4.11; <i>p</i> = 0.02) after adjusting for adiponectin, dietary energy intakes, gender, weight, and age. <b>Conclusions</b>: The GG genotype of rs17300539 is associated with hypertriglyceridaemia, insulin resistance, low adiponectin levels, and a high risk of metabolic syndrome and its components.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2024-11-13T22:16:16.37Z","creation":"2024-11-13T22:16:16.37Z"},"accession":"S-EPMC10746109","cross_references":{"pubmed":["38140287"],"doi":["10.3390/nu15245028"]}}